Forward as One: Integrating Innovation into Europe’s Healthcare Systems. That is the overall theme of the European Alliance for Personalised Medicine’s (EAPM) 2nd Annual Congress, organized from 26-28 November in Milan, Italy. EAPM is a HARMONY Partner.
Personalised medicine is in the news more-and-more often these days, with its goal of giving the right treatment to the right patient at the right time. Breakthroughs in genetics, calls for more and better screening, developments in imaging techniques and the emergence of what we now call ‘Big Data’ have already changed the world of healthcare forever. More than 1000 Life Sciences thought leaders will convene at the Congress, to be held at the Palazzo Lombardia. As it did last year in Belfast, the annual event will bring together key audiences who contribute to the vast programme content and vital knowledge exchange.
More than ever this year, a focus will be on the upcoming European Parliament elections and the installation of a new College of Commissioners, tasked with devising and implementing regulatory frameworks in all areas, including certain aspects of health. More than 700 MEPS will be elected next summer and the Commission will also have a new president as Jean-Claude Juncker steps down. One of the goals of Congress is to engage politicians and lawmakers in the fast-growing field of personalised medicine, and deliver political asks through our consensus-based process.
Europe needs to grasp the fact that health equals wealth and that investment in research and innovation, alongside laws and rules that are fit-for-purpose and reflect the swiftly changing world of medicine, are vital. Hence our continued interaction with MEPs, Commissioners and Member State health leaders.
HARMONY is very interested to connect with the EAPM2018 participants.
Prof. Lars Bullinger, Charite, HARMONY Partner is presenting in the EAPM Session: Private Investment to Drive Forward Healthcare
About EAPM: The European Alliance for Personalised Medicine (EAPM) is a Brussels-based organisation consisting of patients, academics, healthcare professionals, researchers, industry representatives and more, from 40 different stakeholder groups. Its goal is the integration of personalised medicine into Europe’s healthcare systems. The Alliance meets regularly with legislators/ regulators to explain the stakeholder perspective from a consensus-based platform.
Receive the latest news. Click here to subscribe!
Public-private partnership for Big Data in Hematology
HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
HARMONY Coordination Office
Institute of Biomedical Research of
Salamanca (IBSAL)
Salamanca, Spain
HARMONY Communications
European Hematology Association (EHA)
The Hague, The Netherlands
